Pyrazolopyrimidine CDK Inhibitors for Selective Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with cyclin-dependent kinases (CDKs) lack effective inhibitors, particularly for conditions like cancer, inflammation, and neurodegenerative diseases, necessitating the development of new compounds and therapies.
Innovation Solution
The development of novel pyrazolo[1,5-a]pyrimidine compounds as protein kinase inhibitors, which can be used in pharmaceutical compositions to treat proliferative diseases, including cancer, inflammation, and neurodegenerative disorders, by targeting CDKs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors (flavopiridol, olomoucine, roscovitine) are used, then some CDK activity inhibition is achieved, but they lack selectivity and effectiveness for specific cancer types and diseases
Solution Approach 1:
The patent applies local quality by designing pyrazolo[1,5-a]pyrimidine compounds with specific substituent patterns at defined positions (R1-R6) to achieve selective inhibition of particular CDK isoforms. The structured approach with defined variable positions allows optimization for specific disease targets while maintaining a core pharmacophore structure.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical substituents (R1-R6) on the pyrazolo[1,5-a]pyrimidine core structure to modulate inhibitory activity, selectivity, and pharmacokinetic properties. This allows tailoring compounds for specific CDK isoforms and disease indications.
2Adaptability or versatility
If broad-spectrum CDK inhibition is pursued, then multiple disease indications may be covered, but selectivity for specific CDK isoforms decreases leading to off-target effects
Solution Approach 1:
The patent uses local quality by introducing specific substituent groups at defined positions on the pyrazolo[1,5-a]pyrimidine ring to enhance selectivity for particular CDK isoforms. This localized modification allows differentiation between CDK isoforms while maintaining broad disease applicability.
Solution Approach 2:
The patent applies segmentation by dividing the inhibitor design into a core pyrazolo[1,5-a]pyrimidine structure and variable substituent regions (R1-R6). This modular approach allows independent optimization of selectivity and activity for different CDK targets.
3Adaptability or versatility
If new pyrazolo[1,5-a]pyrimidine compounds are developed, then disease treatment options are expanded, but development time and complexity increase
Solution Approach 1:
The patent applies universality by creating a multi-functional pyrazolo[1,5-a]pyrimidine core that can inhibit multiple CDK isoforms and address various disease indications. The structured variable positions (R1-R6) allow a single compound class to serve multiple therapeutic purposes.
Solution Approach 2:
The patent uses segmentation by organizing the compound structure into a standardized core with defined variable regions, facilitating systematic drug discovery and reducing overall development complexity despite the broad therapeutic scope.
Data Source
AI summary
In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.